NASDAQ: MIRMMirum Pharmaceuticals Inc Stock
$95.48+1.89 (+2.02%)
Updated Jun 9, 2026
MIRM Price
$95.48
Fair Value Price
N/A
Market Cap
$5.82B
52 Week Low
$47.79
52 Week High
$114.99
P/E
-7.02x
P/B
24.01x
P/S
9.55x
PEG
N/A
Dividend Yield
N/A
Revenue
$569.61M
Earnings
-$798.84M
Gross Margin
81.4%
Operating Margin
-137.47%
Profit Margin
-140.2%
Debt to Equity
2.67
Operating Cash Flow
-$171M
Beta
0.74
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MIRM Overview
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MIRM's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
MIRM
Ranked#278 of 460
Ranked#278 of 460
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $229.19 | A | |
| $52.99 | A | |
| $15.78 | A |
Be the first to know about important MIRM news, forecast changes, insider trades & much more!
MIRM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MIRM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MIRM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MIRM is poor value based on its book value relative to its share price (24.01x), compared to the US Biotechnology industry average (4.77x)
P/B vs Industry Valuation
MIRM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MIRM due diligence checks available for Premium users.
Valuation
MIRM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.02x
Industry
17.38x
Market
14.33x
MIRM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
24.01x
Industry
4.77x
MIRM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MIRM's financial health
Profit margin
Revenue
$159.9M
Net Income
-$790.2M
Profit Margin
-494.2%
MIRM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MIRM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$890.9M
Liabilities
$648.4M
Debt to equity
2.67
MIRM's short-term assets ($569.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MIRM's short-term assets ($569.44M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MIRM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MIRM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$228.8M
Investing
-$11.6M
Financing
$270.1M
MIRM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MIRM vs Biotech Stocks
Mirum Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.